About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.
As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning BAX 326, an investigational recombinant factor IX (rFIX) protein, as well as Baxter’s partnership with Chatham Therapeutics, LLC to develop a gene therapy-based treatment for hemophilia B. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; additional clinical results; changes in laws and regulations; product quality or patient safety issues; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.1 Frequently Asked Questions About Hemophilia. World Federation of Hemophilia. Accessed on November 28, 2012. Available at: http://www.wfh.org/en/page.aspx?pid=637 2 World Federation of Hemophilia Report on the Annual Global Survey 2010. World Federation of Hemophilia. Accessed on November 28, 2012. Available at: http://www1.wfh.org/publications/files/pdf-1427.pdf 3 Lee, C. A. (2011) Hemophilia Care in the Modern World, in Current and Future Issues in Hemophilia Care (eds E.-C. Rodríguez-Merchán and L. A. Valentino), Wiley-Blackwell, Oxford, UK. Chapter 29. Accessed on November 28, 2012.